Every 10-Q that Amphastar Pharmaceuticals, Inc. (AMPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AMPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMPH filings page.
Amphastar Pharmaceuticals, Inc. reported Q2 2026 net revenues of $183,903 thousand, up from $174,414 thousand, with net income of $30,348 thousand versus $31,030 thousand a year earlier. Diluted EPS was $0.67 compared with $0.64. For the first six months, revenue rose to $355,074 thousand from $344,942 thousand, while net income decreased to $36,768 thousand from $56,315 thousand as higher cost of revenues and operating expenses reduced income from operations to $53,359 thousand from $79,477 thousand.
Cash and cash equivalents were $223,614 thousand at June 30, 2026, up from $170,177 thousand at year-end, and short-term investments were $66,509 thousand. Long-term debt, including $345,000 thousand of 2029 Convertible Notes and a $250,000 thousand term loan, was $609,564 thousand net of issuance costs. Net cash provided by operating activities improved to $99,164 thousand in the first half from $70,669 thousand, while share repurchases reached 3,656,720 shares for $74,705 thousand.
The company reached the first BAQSIMI® annual net sales milestone of $175.0 million, triggering a $100.0 million payment to Eli Lilly allocated primarily to BAQSIMI® product rights. BAQSIMI® generated $77,937 thousand of revenue in the first half, while growth in other products and new ipratropium bromide sales offset declines in Primatene MIST® and glucagon revenue. United States operations contributed $331,382 thousand of first-half revenue.
Amphastar Pharmaceuticals reported sharply lower profitability for the quarter ended March 31, 2026 despite essentially flat sales. Net revenues were $171.2 million versus $170.5 million a year earlier, but net income fell to $6.4 million from $25.3 million as cost of revenues and operating expenses increased.
Gross profit declined to $70.3 million from $85.3 million, while research and development, general and administrative, and other costs all rose. Diluted earnings per share were $0.14 compared with $0.51. Operating cash flow improved to $47.8 million, and the company ended the quarter with $171.2 million in cash, cash equivalents, and restricted cash and total assets of $1.65 billion, including significant BAQSIMI® product rights.
Amphastar Pharmaceuticals reported Q3 2025 results. Net revenues were $191,840 thousand, with gross profit of $98,646 thousand and income from operations of $25,320 thousand. Net income was $17,350 thousand, or diluted EPS of $0.37.
Year to date, net revenues totaled $536,782 thousand and net income was $73,665 thousand. Q3 product mix included BAQSIMI at $53,608 thousand, Primatene MIST at $28,808 thousand, Lidocaine at $12,932 thousand, Epinephrine at $18,789 thousand, Glucagon at $13,558 thousand, and other products at $64,145 thousand.
Cash and cash equivalents were $216,265 thousand, short‑term investments $59,944 thousand, and inventories $185,932 thousand as of September 30, 2025. Total assets were $1,666,222 thousand. Long‑term debt (including the 2.00% 2029 convertible notes and a term loan) totaled $619,798 thousand, with long‑term debt, net of issuance costs and current portion, at $608,582 thousand. Operating cash flow for the nine months was $123,252 thousand. The company repurchased $55,070 thousand of shares year to date; treasury stock stood at $(387,653) thousand. Common shares outstanding were 45,952,174 as of October 31, 2025.